• Something wrong with this record ?

Towards rational design of API-poly(D, L-lactide-co-glycolide) based micro- and nanoparticles: The role of API-polymer compatibility prediction

A. Iemtsev, ALV. Zumaya, M. Dinh, F. Hassouna, M. Fulem

. 2024 ; 650 (-) : 123724. [pub] 20231218

Language English Country Netherlands

Document type Journal Article

Due to their unique properties, such as controlled drug release and improved bioavailability, polymeric microparticles and nanoparticles (MPs and NPs) have gained considerable interest in the pharmaceutical industry. Nevertheless, the high costs associated with biodegradable polymers and the active pharmaceutical ingredients (APIs) used for treating serious diseases, coupled with the vast number of API-polymer combinations, make the search for effective API-polymer MPs and NPs a costly and time-consuming process. In this work, the correlation between the compatibility of selected model APIs (i.e., ibuprofen, naproxen, paracetamol, and indomethacin) with poly(lactide-co-glycolide) (PLGA) derived from respective binary phase diagrams and characteristics of prepared MPs and NPs, such as the drug loading and solid-state properties, was investigated to probe the possibility of implementing the modeling of API-polymer thermodynamic and kinetic phase behavior as part of rational design of drug delivery systems based on MPs and NPs. API-PLGA-based MPs and NPs were formulated using an emulsion-solvent evaporation technique and were characterized for morphology, mean size, zeta potential, drug loading, and encapsulation efficiency. The solid-state properties of the encapsulated APIs were assessed using differential scanning calorimetry and X-ray powder diffraction. The evaluated compatibility was poor for all considered API-PLGA pairs, which is in alignment with the experimental results showing low drug loading in terms of amorphous API content. At the same time, drug loading of the studied APIs in terms of amorphous content was found to follow the same trend as their solubility in PLGA, indicating a clear correlation between API solubility in PLGA and achievable drug loading. These findings suggest that API-polymer phase behavior modeling and compatibility screening can be employed as an effective preformulation tool to estimate optimum initial API concentration for MP and NP preparation or, from a broader perspective, to tune or select polymeric carriers offering desired drug loading.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007518
003      
CZ-PrNML
005      
20240423160029.0
007      
ta
008      
240412e20231218ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijpharm.2023.123724 $2 doi
035    __
$a (PubMed)38123107
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Iemtsev, Anton $u Department of Physical Chemistry, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic
245    10
$a Towards rational design of API-poly(D, L-lactide-co-glycolide) based micro- and nanoparticles: The role of API-polymer compatibility prediction / $c A. Iemtsev, ALV. Zumaya, M. Dinh, F. Hassouna, M. Fulem
520    9_
$a Due to their unique properties, such as controlled drug release and improved bioavailability, polymeric microparticles and nanoparticles (MPs and NPs) have gained considerable interest in the pharmaceutical industry. Nevertheless, the high costs associated with biodegradable polymers and the active pharmaceutical ingredients (APIs) used for treating serious diseases, coupled with the vast number of API-polymer combinations, make the search for effective API-polymer MPs and NPs a costly and time-consuming process. In this work, the correlation between the compatibility of selected model APIs (i.e., ibuprofen, naproxen, paracetamol, and indomethacin) with poly(lactide-co-glycolide) (PLGA) derived from respective binary phase diagrams and characteristics of prepared MPs and NPs, such as the drug loading and solid-state properties, was investigated to probe the possibility of implementing the modeling of API-polymer thermodynamic and kinetic phase behavior as part of rational design of drug delivery systems based on MPs and NPs. API-PLGA-based MPs and NPs were formulated using an emulsion-solvent evaporation technique and were characterized for morphology, mean size, zeta potential, drug loading, and encapsulation efficiency. The solid-state properties of the encapsulated APIs were assessed using differential scanning calorimetry and X-ray powder diffraction. The evaluated compatibility was poor for all considered API-PLGA pairs, which is in alignment with the experimental results showing low drug loading in terms of amorphous API content. At the same time, drug loading of the studied APIs in terms of amorphous content was found to follow the same trend as their solubility in PLGA, indicating a clear correlation between API solubility in PLGA and achievable drug loading. These findings suggest that API-polymer phase behavior modeling and compatibility screening can be employed as an effective preformulation tool to estimate optimum initial API concentration for MP and NP preparation or, from a broader perspective, to tune or select polymeric carriers offering desired drug loading.
650    12
$a polymery $x chemie $7 D011108
650    _2
$a kopolymer kyseliny glykolové a mléčné $x chemie $7 D000077182
650    _2
$a lékové transportní systémy $x metody $7 D016503
650    12
$a nanočástice $x chemie $7 D053758
650    _2
$a léčivé přípravky $7 D004364
650    _2
$a velikost částic $7 D010316
650    _2
$a nosiče léků $x chemie $7 D004337
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zumaya, Alma Lucia Villela $u Faculty of Chemical Engineering, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic
700    1_
$a Dinh, Martin $u Department of Physical Chemistry, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic
700    1_
$a Hassouna, Fatima $u Faculty of Chemical Engineering, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic. Electronic address: hassounf@vscht.cz
700    1_
$a Fulem, Michal $u Department of Physical Chemistry, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic. Electronic address: fulemm@vscht.cz
773    0_
$w MED00002359 $t International journal of pharmaceutics $x 1873-3476 $g Roč. 650 (20231218), s. 123724
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38123107 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160025 $b ABA008
999    __
$a ok $b bmc $g 2081489 $s 1217285
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 650 $c - $d 123724 $e 20231218 $i 1873-3476 $m International journal of pharmaceutics $n Int. j. pharm. $x MED00002359
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...